Cover Image
市場調查報告書

輕度乾癬 - 開發中產品分析

Mild Psoriasis - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 321922
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
輕度乾癬 - 開發中產品分析 Mild Psoriasis - Pipeline Review, H2 2015
出版日期: 2015年11月25日 內容資訊: 英文 48 Pages
簡介

乾癬是指發炎造成發紅的皮膚上出現肥厚的白色鱗屑之疾病,如果不到體表3%便稱為輕度乾癬。症狀除了上述之外更有乾裂的皮膚出血、搔癢感、熱感、疼痛、腫、關節發硬等。

本報告提供輕度乾癬治療藥的開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

輕度乾癬概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

治療藥的開發企業

  • Avexxin AS
  • Convoy Therapeutics, Inc.
  • Delenex Therapeutics AG
  • GlycoMar Limited
  • OPKO Health, Inc.
  • Soligenix, Inc.
  • UCB S.A.

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AKP-11
  • AVX-001
  • cyclosporine
  • DLX-105
  • DLX-3003
  • GLY-2028
  • lunacalcipol
  • SGX-301
  • UCB-5857

最新的開發平台資訊

開發暫停中的計劃

開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7378IDB

Summary

Global Markets Direct's, 'Mild Psoriasis - Pipeline Review, H2 2015', provides an overview of the Mild Psoriasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mild Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mild Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mild Psoriasis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Mild Psoriasis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Mild Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Mild Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Mild Psoriasis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Mild Psoriasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mild Psoriasis Overview
  • Therapeutics Development
    • Pipeline Products for Mild Psoriasis - Overview
  • Mild Psoriasis - Therapeutics under Development by Companies
  • Mild Psoriasis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Mild Psoriasis - Products under Development by Companies
  • Mild Psoriasis - Companies Involved in Therapeutics Development
    • Almirall, S.A.
    • Avexxin AS
    • Convoy Therapeutics, Inc.
    • Crescendo Biologics Limited
    • Delenex Therapeutics AG
    • GlycoMar Limited
    • OPKO Health, Inc.
    • Soligenix, Inc.
  • Mild Psoriasis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AKP-11 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AVX-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DLX-105 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLY-2028 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lunacalcipol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SGX-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tazarotene - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Mild Psoriasis - Recent Pipeline Updates
  • Mild Psoriasis - Dormant Projects
  • Mild Psoriasis - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Mild Psoriasis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Mild Psoriasis - Pipeline by Almirall, S.A., H2 2015
  • Mild Psoriasis - Pipeline by Avexxin AS, H2 2015
  • Mild Psoriasis - Pipeline by Convoy Therapeutics, Inc., H2 2015
  • Mild Psoriasis - Pipeline by Crescendo Biologics Limited, H2 2015
  • Mild Psoriasis - Pipeline by Delenex Therapeutics AG, H2 2015
  • Mild Psoriasis - Pipeline by GlycoMar Limited, H2 2015
  • Mild Psoriasis - Pipeline by OPKO Health, Inc., H2 2015
  • Mild Psoriasis - Pipeline by Soligenix, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Mild Psoriasis Therapeutics - Recent Pipeline Updates, H2 2015
  • Mild Psoriasis - Dormant Projects, H2 2015
  • Mild Psoriasis - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Mild Psoriasis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top